Nanoparticle-based delivery for the treatment of inner ear disorders

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 19, Issue 5, 2011, Pages 388-396

  Pyykkö, Ilmari ^a,b   Zou, Jing ^a   Zhang, Weikai ^a   Zhang, Ya ^a  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

gene therapy; internalization; nanogels; nanoparticles; Piggy Bac; targetability; transfection

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CAVEOLIN; CHITOSAN; CLATHRIN; GREEN FLUORESCENT PROTEIN; GROWTH FACTOR; HYPERBRANCHED POLYLYSINE; LIPOSOME; MATH 1; NANOCARRIER; NANOGEL; NANOPARTICLE; NERVE GROWTH FACTOR DERIVED PEPTIDE; PEPTIDE; POLYETHYLENEIMINE; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYMER; PRESTIN; PROTEIN; PROTEIN P57; SHORT HAIRPIN RNA; SOLID LIPID NANOPARTICLE; STEROID; SUPERPARAMAGNETIC IRON OXIDE; TET1 PEPTIDE; TRANS ACTING ACTIVATOR OF TRANSCRIPTION PEPTIDE; TRISIALOGANGLIOSIDE CLOSTRIDIAL TOXIN; TROPOMYOCIN RECEPTOR KINASE B; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BIODEGRADABILITY; CELL INTERACTION; CELL MIGRATION; COCHLEAR NERVE; CONJUGATION; DNA TRANSFECTION; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TARGETING; ENDOCYTOSIS; ENDOSOME; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HAIR CELL; HUMAN; HYDROGEL; IMAGING; INNER EAR DISEASE; INTERNALIZATION; LIGAND BINDING; LIPID RAFT; MEMBRANE; NANOENCAPSULATION; NANOFABRICATION; NERVE CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BINDING; REPORTER GENE; REVIEW; ROUND WINDOW MEMBRANE; SPIRAL GANGLION; STEM CELL; SURFACE PROPERTY; TRANSTYMPANIC DELIVERY;

ANIMALS; BIOLOGICAL TRANSPORT; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LABYRINTH DISEASES; NANOMEDICINE; NANOPARTICLES; TISSUE DISTRIBUTION; TRANSFECTION;

EID: 80052729461     PISSN: 10689508     EISSN: 15316998     Source Type: Journal    
DOI: 10.1097/MOO.0b013e32834aa3a8     Document Type: Review

References (92)

1. Braun S. Muscular gene transfer using nonviral vectors. Curr Gene Ther 2008; 8:391-405.
2. Soininen P, Hanzlikova M, Paukkunen M, et al. Sample purification improves the analysis of nonviral in vivo gene transfection. Plasmid 2010; 63:27-30.
3. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem 2005; 74:711-738. (Pubitemid 40995522)
4. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80:148-158. (Pubitemid 37272241)
5. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4:346-358. (Pubitemid 36538359)
6. Anderson WF. Human gene therapy. Nature 1998; 392:25-30. (Pubitemid 28215190)
7. Ferber D. Gene therapy: safer and virus-free? Science 2001; 294:1638-1642. (Pubitemid 33104814)
8. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002; 9:1647-1652. (Pubitemid 36104607)
9. Schmidt-Wolf GD, Schmidt-Wolf IG. Nonviral and hybrid vectors in human gene therapy: an update. Trends Mol Med 2003; 9:67-72. (Pubitemid 36313867)
10. Farjo R, Skaggs J, Quiambao AB, et al. Efficient nonviral ocular gene transfer with compacted DNA nanoparticles. PLoS One 2006; 1:e38.
11. Ziady AG, Gedeon CR, Miller T, et al. Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo. Mol Ther 2003; 8:936-947. (Pubitemid 38072306)
12. Wang Y, Gao S, Ye WH, et al. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006; 5:791-796. (Pubitemid 44570860)
13. de la Fuente M, Csaba N, Garcia-Fuentes M, et al. Nanoparticles as protein and gene carriers to mucosal surfaces. Nanomedicine (Lond) 2008; 3:845-857.
14. Tros de Ilarduya C, Sun Y, Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci 2010; 40:159-170.
15. Godbey WT, Mikos AG. Recent progress in gene delivery using nonviral transfer complexes. J Control Release 2001; 72:115-125. (Pubitemid 32522349)
16. Zou J, Saulnier P, Perrier T, et al. Distribution of lipid nanocapsules in different cochlear cell populations after round window membrane permeation. J Biomed Mater Res B Appl Biomater 2008; 87:10-18.
17. Zhang W, Zhang Y, Sood R, et al. Visualization of intracellular trafficking of Math1 protein in different cell types with a newly-constructed nonviral gene delivery plasmid. J Gene Med 2011; 13:134-144.
18. Scheper V, Wolf M, Scholl M, et al. Potential novel drug carriers for inner ear treatment: hyperbranched polylysine and lipid nanocapsules. Nanomedicine (Lond) 2009; 4:623-635.
19. Sakamoto T, Nakagawa T, Horie RT, et al. Inner ear drug delivery system from the clinical point of view. Acta Otolaryngol Suppl 2010; 130:101-104.
20. Roy S, Johnston AH, Newman TA, et al. Cell-specific targeting in the mouse inner ear using nanoparticles conjugated with a neurotrophin-derived peptide ligand: potential tool for drug delivery. Int J Pharm 2010; 390:214-224.
21. Sun H, Huang A, Cao S. Current status and prospects of gene therapy for the inner ear. Hum Gene Ther 2011; 22:1-12.
22. Chen G, Zhang X, Yang F, et al. Disposition of nanoparticle-based delivery system via inner ear administration. Curr Drug Metab 2010; 11:886-897.
23. Okano T, Nakagawa T, Kita T, et al. Cell-gene delivery of brain-derived neurotrophic factor to the mouse inner ear. Mol Ther 2006; 14:866-871. (Pubitemid 44743126)
24. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev 2009; 109:259-302.
25. Committee for Medicinal Products for Human Use (CHMP). Reflection paper on nanotechnology-based medicinal products for human use. In EMEA/ CHMP/79769/2006; 2006. www.ema.europa.eu/docs/en-GB/document-library/Report/ 2010/01/WC500069730.pdf
26. Zou J, Sood R, Ranjan S, et al. Manufacturing and in vivo inner ear visualization of MRI traceable liposome nanoparticles encapsulating gadolinium. J Nanobiotechnol 2011; 8:32.
27. Abdel-Mottaleb MM, Neumann D, Lamprecht A. In vitro drug release mechanism from lipid nanocapsules (LNC). Int J Pharm 2010; 390:208-213.
28. Tan BT, Foong KH, Lee MM, et al. Polyethylenimine-mediated cochlear gene transfer in guinea pigs. Arch Otolaryngol Head Neck Surg 2008; 134:884-891.
29. Horie RT, Sakamoto T, Nakagawa T, et al. Sustained delivery of lidocaine into the cochlea using poly lactic/glycolic acid microparticles. Laryngoscope 2010; 120:377-383.
30. Inkinen S, Hakkarainen M, Albertsson AC, et al. From lactic acid to poly(lactic acid) (PLA): characterization and analysis of PLA and its precursors. Biomacromolecules 2011; 12:523-532.
31. Arya G, Vandana M, Acharya S et al. Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine 2011 (in press).
32. Zhang W, Zhang Y, Lobler M, et al. Nuclear entry of hyperbranched polylysine nanoparticles into cochlear cells. Int J Nanomedicine 2011; 6:535-546.
33. Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. J Pharm Sci 2003; 92:1343-1355. (Pubitemid 36792748)
34. Zhang Y, Zhang W, Johnston AH, et al. Improving the visualization of fluorescently tagged nanoparticles and fluorophore-labeled molecular probes by treatment with CuSO(4) to quench autofluorescence in the rat inner ear. Hear Res 2010; 269:1-11.
35. Yu T, Malugin A, Ghandehari H. Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS Nano 2011 (in press).
36. Kopke RD, Wassel RA, Mondalek F, et al. Magnetic nanoparticles: inner ear targeted molecule delivery and middle ear implant. Audiol Neurootol 2006; 11:123-133. (Pubitemid 43168184)
37. Segat D, Tavano R, Donini M et al. Proinflammatory effects of bare and PEGylated ORMOSIL-, PLGA- and SUV-NPs on monocytes and PMNs and their modulation by f-MLP. Nanomedicine (Lond) 2011 (in press).
38. Beduneau A, Saulnier P, Anton N, et al. Pegylated nanocapsules produced by an organic solvent-free method: Evaluation of their stealth properties. Pharm Res 2006; 23:2190-2199.
39. Guo S, Huang Y, Zhang W, et al. Ternary complexes of amphiphilic polycaprolactone- graft-poly (N,N-dimethylaminoethyl methacrylate), DNA and polyglutamic acid-graft-poly(ethylene glycol) for gene delivery. Biomaterials 2011; 32:4283-4292.
40. Beduneau A, Saulnier P, Hindre F, et al. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments. Biomaterials 2007; 28:4978-4990. (Pubitemid 47371148)
41. Pittella F, Zhang M, Lee Y, et al. Enhanced endosomal escape of siRNAincorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity. Biomaterials 2011; 32:3106-3114.
42. Nakase I, Kobayashi S, Futaki S. Endosome-disruptive peptides for improving cytosolic delivery of bioactive macromolecules. Biopolymers 2010; 94:763-770.
43. Kabanov AV, Vinogradov SV. Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew Chem Int Ed Engl 2009; 48:5418-5429.
44. Nie S, Hsiao WL, Pan W, et al. Thermoreversible Pluronic F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies. Int J Nanomedicine 2011; 6:151-166.
45. Pyykko I, Zou J, Poe D, et al. Magnetic resonance imaging of the inner ear in Meniere's disease. Otolaryngol Clin North Am 2010; 43:1059-1080.
46. Thaler M, Roy S, Fornara A, et al. Visualization and analysis of superparamagnetic iron oxide nanoparticles in the inner ear by light microscopy and energy filtered TEM. Nanomedicine 2011; 7:360-369.
47. Li WM, Mayer LD, Bally MB. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther 2002; 300:976-983. (Pubitemid 34165004)
48. Zou J, Sood R, Ranjan S, et al. Manufacturing and in vivo inner ear visualization of MRI traceable liposome nanoparticles encapsulating gadolinium. J Nanobiotechnology 2010; 8:32.
49. Gref R, Luck M, Quellec P, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 2000; 18:301-313. (Pubitemid 30479870)
50. Rothschild G, Zhao X, Iavarone A, et al. E Proteins and Id2 converge on p57Kip2 to regulate cell cycle in neural cells. Mol Cell Biol 2006; 26:4351-4361. (Pubitemid 43788033)
51. Salt AN, Ma Y. Quantification of solute entry into cochlear perilymph through the round window membrane. Hear Res 2001; 154:88-97. (Pubitemid 32567538)
52. Engmer C, Laurell G, Bagger-Sjoback D, et al. Immunodefense of the round window. Laryngoscope 2008; 118:1057-1062. (Pubitemid 351787278)
53. Goycoolea MV, Lundman L. Round window membrane. Structure function and permeability: a review. Microsc Res Tech 1997; 36:201-211. (Pubitemid 27120351)
54. Dispenza F, Amodio E, De Stefano A, et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy, a randomized clinical study. Eur Arch Otorhinolaryngol 2011 (in press).
55. Mikulec AA, Plontke SK, Hartsock JJ, et al. Entry of substances into perilymph through the bone of the otic capsule after intratympanic applications in guinea pigs: implications for local drug delivery in humans. Otol Neurotol 2009; 30:131-138.
56. Paasche G, Tasche C, Stover T, et al. The long-term effects of modified electrode surfaces and intracochlear corticosteroids on postoperative impedances in cochlear implant patients. Otol Neurotol 2009; 30:592-598.
57. Agterberg MJ, Versnel H, van Dijk LM, et al. Enhanced survival of spiral ganglion cells after cessation of treatment with brain-derived neurotrophic factor in deafened guinea pigs. J Assoc Res Otolaryngol 2009; 10:355-367.
58. Leroueil PR, Berry SA, Duthie K, et al. Wide varieties of cationic nanoparticles induce defects in supported lipid bilayers.Nano Lett 2008; 8:420-424. (Pubitemid 351345993)
59. Villanueva A, Canete M, Roca AG, et al. The influence of surface functionalization on the enhanced internalization of magnetic nanoparticles in cancer cells. Nanotechnology 2009; 20:115103.
60. Medina-Kauwe LK, Xie J, Hamm-Alvarez S. Intracellular trafficking of nonviral vectors. Gene Ther 2005; 12:1734-1751. (Pubitemid 41760286)
61. Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 2010; 6:12-21.
62. Shinohara T, Bredberg G, Ulfendahl M, et al. Neurotrophic factor intervention restores auditory function in deafened animals. Proc Natl Acad Sci U S A 2002; 99:1657-1660. (Pubitemid 34136548)
63. Rask-Andersen H, Bostrom M, Gerdin B, et al. Regeneration of human auditory nerve. In vitro/in video demonstration of neural progenitor cells in adult human and guinea pig spiral ganglion. Hear Res 2005; 203:180-191. (Pubitemid 40602827)
64. Oshima K, Senn P, Heller S. Isolation of sphere-forming stem cells from the mouse inner ear. Methods Mol Biol 2009; 493:141-162.
65. Senn P, Heller S. Stem-cell-based approaches for treating inner ear diseases [in German]. HNO 2008; 56:21-26.
66. Bitsche M, Dudas J, Roy S, et al. Neurotrophic receptors as potential therapy targets in postnatal development, in adult, and in hearing loss-affected inner ear. Otol Neurotol 2011; 32:761-773.
67. Liu JK, Teng Q, Garrity-Moses M, et al. A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting. Neurobiol Dis 2005; 19:407-418. (Pubitemid 40968054)
68. Kwon EJ, Lasiene J, Jacobson BE, et al. Targeted nonviral delivery vehicles to neural progenitor cells in the mouse subventricular zone. Biomaterials 2010; 31:2417-2424.
69. Park IK, Lasiene J, Chou SH, et al. Neuron-specific delivery of nucleic acids mediated by Tet1-modified poly(ethylenimine). J Gene Med 2007; 9:691-702. (Pubitemid 47288827)
70. Murakoshi M, Iida K, Kumano S, et al. Immune atomic force microscopy of prestin-transfected CHO cells using quantum dots. Pflugers Arch 2009; 457:885-898.
71. Dean DA, Strong DD, Zimmer WE. Nuclear entry of nonviral vectors. Gene Ther 2005; 12:881-890. (Pubitemid 40852206)
72. Ruponen M, Arkko S, Urtti A, et al. Intracellular DNA release and elimination correlate poorly with transgene expression after nonviral transfection. J Control Release 2009; 136:226-231.
73. Hatakeyama H, Ito E, Akita H, et al. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J Control Release 2009; 139:127-132.
74. Li W, Nicol F, Szoka FC Jr. GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv Drug Deliv Rev 2004; 56:967-985. (Pubitemid 38520204)
75. Shin J, Shum P, Thompson DH. Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. J Control Release 2003; 91:187-200. (Pubitemid 37288890)
76. Verkman AS. Solute and macromolecule diffusion in cellular aqueous compartments. Trends Biochem Sci 2002; 27:27-33. (Pubitemid 34131622)
77. Lukacs GL, Haggie P, Seksek O, et al. Size-dependent DNA mobility in cytoplasm and nucleus. J Biol Chem 2000; 275:1625-1629. (Pubitemid 30060778)
78. Ludtke JJ, Zhang G, Sebestyen MG, et al. A nuclear localization signal can enhance both the nuclear transport and expression of 1 kb DNA. J Cell Sci 1999; 112 (Pt 12):2033-2041. (Pubitemid 29338827)
79. Pante N, Kann M. Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm. Mol Biol Cell 2002; 13:425-434. (Pubitemid 34165072)
80. Rudolph C, Schillinger U, Ortiz A, et al. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm Res 2004; 21:1662-1669. (Pubitemid 41184398)
81. Fittipaldi A, Ferrari A, Zoppe M, et al. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 2003; 278:34141-34149. (Pubitemid 37553255)
82. Ferrari A, Pellegrini V, Arcangeli C, et al. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol Ther 2003; 8:284-294. (Pubitemid 37062838)
83. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004; 10:310-315. (Pubitemid 38667624)
84. Richard JP, Melikov K, Brooks H, et al. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 2005; 280:15300-15306. (Pubitemid 40562886)
85. Saalik P, Elmquist A, Hansen M, et al. Protein cargo delivery properties of cellpenetrating peptides. A comparative study. Bioconjug Chem 2004; 15:1246-1253. (Pubitemid 39552013)
86. Jarver P, Langel U. The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov Today 2004; 9:395-402. (Pubitemid 38479684)
87. Lindsay MA. Peptide-mediated cell delivery: application in protein target validation. Curr Opin Pharmacol 2002; 2:587-594.
88. Koppelhus U, Awasthi SK, Zachar V, et al. Cell-dependent differential cellular uptake of PNA, peptides, and PNA-peptide conjugates. Antisense Nucleic Acid Drug Dev 2002; 12:51-63. (Pubitemid 34627600)
89. Nakase I, Niwa M, Takeuchi T, et al. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 2004; 10:1011-1022. (Pubitemid 39625245)
90. Rinne J, Albarran B, Jylhava J, et al. Internalization of novel nonviral vector TAT-streptavidin into human cells. BMC Biotechnol 2007; 7:1.
91. Kim A, Pyykko I. Size matters: versatile use of PiggyBac transposons as a genetic manipulation tool. Mol Cell Biochem 2011; 354:301-309.
92. Poe P, Zou J, Zhang W, et al. MRI of the cochlea with superparamagnetic iron oxide nanoparticles compared to gadolinium chelate contrast agents in a rat model. Eur J Nanomed 2009; 2:29-36.